scholarly journals Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

2009 ◽  
Vol 69 (2) ◽  
pp. 400-408 ◽  
Author(s):  
X Mariette ◽  
F Tubach ◽  
H Bagheri ◽  
M Bardet ◽  
J M Berthelot ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Inflammatory Diseases ◽  
Antibody Therapy ◽  
Case Control ◽  
Hodgkin's Lymphoma ◽  
Control Analysis ◽  
Barr Virus ◽  
Increased Risk ◽  
Epstein Barr ◽  
Case Control Analysis

Objective:To describe cases of lymphoma associated with anti-TNF therapy, identify risk factors, estimate the incidence and compare the risks for different anti-TNF agents.Methods:A national prospective registry was designed (Research Axed on Tolerance of bIOtherapies; RATIO) to collect all cases of lymphoma in French patients receiving anti-TNF therapy from 2004 to 2006, whatever the indication. A case–control analysis was conducted including two controls treated with anti-TNF per case and an incidence study of lymphoma with the French population was used as the reference.Results:38 cases of lymphoma, 31 non-Hodgkin’s lymphoma (NHL) (26 B cell and five T cell), five Hodgkin’s lymphoma (HL) and two Hodgkin’s-like lymphoma were collected. Epstein–Barr virus was detected in both of two Hodgkin’s-like lymphoma, three of five HL and one NHL. Patients receiving adalimumab or infliximab had a higher risk than those treated with etanercept: standardised incidence ratio (SIR) 4.1 (2.3–7.1) and 3.6 (2.3–5.6) versus 0.9 (0.4–1.8). The exposure to adalimumab or infliximab versus etanercept was an independent risk factor for lymphoma in the case–control study: odds ratio 4.7 (1.3–17.7) and 4.1 (1.4–12.5), respectively. The sex and age-adjusted incidence rate of lymphoma was 42.1 per 100 000 patient-years. The SIR was 2.4 (95% CI 1.7 to 3.2).Conclusion:The two to threefold increased risk of lymphoma in patients receiving anti-TNF therapy is similar to that expected for such patients with severe inflammatory diseases. Some lymphomas associated with immunosuppression may occur, and the risk of lymphoma is higher with monoclonal-antibody therapy than with soluble-receptor therapy.

scholarly journals Clinical outcome of breast cancer occurring after treatment for Hodgkin's lymphoma: case-control analysis

2009 ◽  
Vol 4 (1) ◽  
pp. 19 ◽  
Author(s):  
Mohamed El-Din ◽  
Kevin S Hughes ◽  
Rita A Raad ◽  
Saveli I Goldberg ◽  
Alan C Aisenberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Hodgkin’S Lymphoma ◽  
Case Control ◽  
Hodgkin's Lymphoma ◽  
Control Analysis ◽  
Case Control Analysis

scholarly journals HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
Caron A. Jacobson ◽  
Jeremy S. Abramson
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Immune Deficiency Syndrome ◽  
Deficiency Syndrome ◽  
Hodgkin's Lymphoma ◽  
Barr Virus ◽  
Improved Outcomes ◽  
Increased Risk ◽  
Immunodeficiency Virus ◽  
Epstein Barr ◽  
Modern Era

Patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) are at increased risk for developing Hodgkin's lymphoma (HL), a risk that has not decreased despite the success of combination antiretroviral therapy (cART) in the modern era. HIV-associated HL (HIV-HL) differs from HL in non-HIV-infected patients in that it is nearly always associated with Epstein-Barr virus (EBV) and more often presents with high-risk features of advanced disease, systemic “B” symptoms, and extranodal involvement. Before the introduction of cART, patients with HIV-HL had lower response rates and worse outcomes than non-HIV-infected HL patients treated with conventional chemotherapy. The introduction of cART, however, has allowed for the delivery of full-dose and dose-intensive chemotherapy regimens with improved outcomes that approach those seen in non-HIV infected patients. Despite these significant advances, HIV-HL patients remain at increased risk for treatment-related toxicities and drug-drug interactions which require careful attention and supportive care to insure the safe administration of therapy. This paper will address the modern diagnosis, risk stratification, and therapy of HIV-associated HL.

scholarly journals Comparison of three methods for the detection of Epstein-Barr virus in Hodgkin’s lymphoma in paraffin-embedded tissues

2012 ◽  
Vol 7 (1) ◽  
pp. 89-92 ◽  
Author(s):  
ZONG-LI QI ◽  
XI-QUN HAN ◽  
JUN HU ◽  
GUANG-HUA WANG ◽  
JIN-WEI GAO ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Epstein Barr Virus ◽  
Hodgkin's Lymphoma ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Association between Epstein-Barr virus and Hodgkin's lymphoma in Belgium: A pathological and virological study

2007 ◽  
Vol 48 (7) ◽  
pp. 1323-1331 ◽  
Author(s):  
Mounir Trimèche ◽  
Christophe Bonnet ◽  
Sadok Korbi ◽  
Jacques Boniver ◽  
Laurence de Leval
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Epstein Barr Virus ◽  
Hodgkin's Lymphoma ◽  
Barr Virus ◽  
Virological Study ◽  
Epstein Barr

scholarly journals The H3K27me3 demethylase, KDM6B, is induced by Epstein–Barr virus and over-expressed in Hodgkin's Lymphoma

Oncogene ◽  
2011 ◽  
Vol 30 (17) ◽  
pp. 2037-2043 ◽  
Author(s):  
J A Anderton ◽  
S Bose ◽  
M Vockerodt ◽  
K Vrzalikova ◽  
W Wei ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Epstein Barr Virus ◽  
Hodgkin's Lymphoma ◽  
Barr Virus ◽  
Epstein Barr

scholarly journals Recent Advances in Diagnostic Approaches for Epstein–Barr Virus

Pathogens ◽  
2020 ◽  
Vol 9 (3) ◽  
pp. 226 ◽  
Author(s):  
Mai Abdel Haleem Abusalah ◽  
Siew Hua Gan ◽  
Mohammad A. I. Al-Hatamleh ◽  
Ahmad Adebayo Irekeola ◽  
Rafidah Hanim Shueb ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Epstein Barr Virus ◽  
Antibody Test ◽  
Hodgkin's Lymphoma ◽  
Sample Type ◽  
Barr Virus ◽  
Advantages And Disadvantages ◽  
Negative Results ◽  
Epstein Barr ◽  
The Impact

Epstein–Barr virus (EBV) is the causative agent of many diseases including infectious mononucleosis (IM), and it is associated with different subtypes of lymphoma, sarcoma and carcinoma such as Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, nasopharyngeal carcinoma, and gastric carcinoma. With the advent of improved laboratory tests for EBV, a timelier and accurate diagnosis could be made to aid better prognosis and effective treatment. For histopathological lesions, the in situ hybridization (ISH) of EBV-encoded RNA (EBER) in biopsy tissues remains the gold standard for detecting EBV. Methods such as the heterophile antibody test, immunofluorescence assays, enzyme immunoassays, Western blot, and polymerase chain reaction (PCR) are also employed in the detection of EBV in different types of samples. The determination of EBV viral load using PCR, however, is gaining more prominence in the diagnosis of EBV-associated diseases. Given the challenge of false positive/negative results that are sometimes experienced during the detection of EBV, variability in results from different laboratories, and the impact of factors such as sample type and the immunological status of patients from whom samples are collected, the need to critically examine these present methods is invaluable. This review thus presents current advances in the detection of EBV, detailing the advantages and disadvantages of the various techniques. In addition, fundamental virological concepts are highlighted to enhance the greater understanding, the proper application, and the interpretation of EBV tests.

scholarly journals Epstein-Barr Virus–Negative Hodgkin's Lymphoma After Mycosis Fungoides: Molecular Evidence for Distinct Clonal Origin

2001 ◽  
Vol 14 (2) ◽  
pp. 91-97 ◽  
Author(s):  
Marcus Kremer ◽  
Michael Sandherr ◽  
Birgit Geist ◽  
Antonello D Cabras ◽  
Heinz Höfler ◽  
...  
Keyword(s):  
Mycosis Fungoides ◽  
Hodgkin’S Lymphoma ◽  
Epstein Barr Virus ◽  
Hodgkin's Lymphoma ◽  
Molecular Evidence ◽  
Barr Virus ◽  
Clonal Origin ◽  
Epstein Barr
Sign in / Sign up

Export Citation Format

Share Document